Covid: Asian vaccine makers' shares fall as US backs patent waiver

U.S. support for a proposal to waive intellectual-property protections for Covid-19 vaccines might be good news for the global inoculation campaign, but it's an unwelcome turn for firms whose share prices have been buoyed by profits from coronavirus shots. Pfizer Inc., BioNTech SE, Novavax Inc. and CureVac NV declined Thursday in U.S. premarket trading. Shanghai Fosun Pharmaceutical Group Co., which has the rights to develop and market BioNTech's shot in China, plunged 14% in Hong Kong, the most ever. With many countries struggling with a resurgence of the virus, U.S. Trade Representative Katherine Tai said Wednesday the Biden administration will…